Efficacy and Safety of Relacorilant in Patients With Adrenal Hypercortisolism: Results From a Phase 3 Study
Hamrahian et al. • 2025 • AACE 2025 Congress
© 2024 Corcept Therapeutics, Incorporated
About jeremiah@devisedesigns.com
This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 151 entries already.
Entries by jeremiah@devisedesigns.com
A Comprehensive Safety Assessment of Relacorilant: Insights From Phase 2 and Phase 3 Trials in Patients With Endogenous Hypercortisolism
Hannoush et al. • 2025 • AACE 2025 Congress
Effect of Hepatic Impairment on the Pharmacokinetics of Miricorilant: Results from a Phase 1, Open-Label, Adaptive-Design Study
Custodio et al. • 2025 • EASL 2025 Congress
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Pivonello et al. • 2025 • ESPE, ESE